GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NeurogesX Inc (OTCPK:NGSX) » Definitions » Earnings Power Value (EPV)

NeurogesX (NeurogesX) Earnings Power Value (EPV) : $-7.11 (As of Dec11)


View and export this data going back to . Start your Free Trial

What is NeurogesX Earnings Power Value (EPV)?

As of Dec11, NeurogesX's earnings power value is $-7.11. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


NeurogesX Earnings Power Value (EPV) Historical Data

The historical data trend for NeurogesX's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeurogesX Earnings Power Value (EPV) Chart

NeurogesX Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeurogesX Semi-Annual Data
Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeurogesX's Earnings Power Value (EPV)

For the Drug Manufacturers - Specialty & Generic subindustry, NeurogesX's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeurogesX's Earnings Power Value (EPV) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NeurogesX's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where NeurogesX's Earnings Power Value (EPV) falls into.



NeurogesX Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

NeurogesX's "Earning Power" Calculation:

Average of Last 5 Years Last Year
Revenue 4.36
DDA 0.32
Operating Margin % -380.24
SGA * 25% 5.14
Tax Rate % 0.00
Maintenance Capex 0.31
Cash and Cash Equivalents 34.31
Short-Term Debt 4.83
Long-Term Debt 62.75
Shares Outstanding (Diluted) 23.01

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = -380.24%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = $4.36 Mil, Average Operating Margin = -380.24%, Average Adjusted SGA = 5.14,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 4.36 * -380.24% +5.14 = $-11.4171391 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 0.00%, and "Normalized" EBIT = $-11.4171391 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = -11.4171391 * ( 1 - 0.00% ) = $-11.4171391 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 0.32 * 0.5 * 0.00% = $0 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = -11.4171391 + 0 = $-11.4171391 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
NeurogesX's Average Maintenance CAPEX = $0.31 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. NeurogesX's current cash and cash equivalent = $34.31 Mil.
NeurogesX's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 62.75 + 4.83 = $67.575 Mil.
NeurogesX's current Shares Outstanding (Diluted Average) = 23.01 Mil.

NeurogesX's Earnings Power Value (EPV) for Dec11 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( -11.4171391 - 0.31)/ 9%+34.31-67.575 )/23.01
=-7.11

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( -7.1102608414333-0.005 )/-7.1102608414333
= N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.


NeurogesX  (OTCPK:NGSX) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


NeurogesX Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of NeurogesX's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.


NeurogesX (NeurogesX) Business Description

Traded in Other Exchanges
N/A
Address
NeurogesX, Inc. was incorporated in California as Advanced Analgesics, Inc. on May 28, 1998 and changed its name to NeurogesX, Inc. in September 2000. In February 2007, it reincorporated into Delaware. It is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. It is assembling a portfolio of pain management product candidates based on known chemical entities to develop innovative new therapies that might offer substantial advantages over currently available treatment options. The Company's initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company's first commercial product, Qutenza, the first prescription strength capsaicin product is a dermal delivery system designed to treat certain neuropathic pain conditions and was approved by the U.S, Food and Drug Administration, or FDA in November 2009 for the management of neuropathic pain associated with postherpetic neuralgia, or PHN. It is currently preparing to commercialize Qutenza in the United States with its own sales force and that Qutenza would be commercially available in the United States in the first half of 2010. Qutenza is a non-narcotic analgesic formulated in a localized treatment patch containing an 8% concentration of synthetic capsaicin. Capsaicin is released from the patch and, with the aid of penetration enhancers, penetrates into the skin during application without significant absorption of capsaicin into the bloodstream. The users of Qutenza are unlikely to experience the common central nervous system side effects of systemically administered drugs used to treat neuropathic pain such as anti-convulsants, anti-depressants and opioids and the potential for abuse and addiction associated with some of these drugs. It is currently evaluating the nature, scope and timing of continued development of Qutenza to support the potential for label expansion in the United States. Areas of potential focus for label expansion include HIV-distal sensory neuropathy, or HIV-DSP, also known as HIV-associated neuropathy, or HIV-AN, painful diabetic neuropathy, or PDN, and potentially other neuropathic pain indications. It expects that Qutenza would compete against, and may be used in combination with, well-established products currently used both on and off-label in its target indications. The most directly competitive currently marketed products in the United States are Lidoderm, an FDA-approved 5% lidocaine topical patch for the treatment of PHN marketed by Endo Pharmaceuticals, and Lyrica, an oral anti-convulsant, marketed by Pfizer for use in the treatment of PHN. Regulation by governmental authorities in the United States and other countries is a significant factor in the development, manufacture and marketing of pharmaceuticals.
Executives
Ron Martell officer: President and CEO PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Stephen F Ghiglieri officer: Exec. V.P., COO & CFO C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Robert Nelsen director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Steven H Nelson director 21650 OXNARD STREET, WOODLAND HILLS CA 91367
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Bradford S Goodwin director 5000 SHORELINE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Jean Jacques Bienaime director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Anthony A Ditonno director, officer: President and CEO C/O OXYGEN BIOTHERAPEUTICS, INC., ONE COPLEY PARKWAY, STE. 490, MORRISVILLE NC 27560
Jeffrey K Tobias officer: CMO, EVP Research & Deve C/O NEUROGESX INC, 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Moshe Arkin 10 percent owner, other: also member of 10% owner group 6 HACHOSHLIM ST., HERZELIA L3 4672406
Keith Crandell 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Clinton Bybee 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Steven Lazarus 10 percent owner 8755 WEST HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners V Llc 10 percent owner C/O ARCH VENTURE PARTNERS, 8755 W. HIGGINS AVE. #1025, CHICAGO IL 60631

NeurogesX (NeurogesX) Headlines

From GuruFocus

NeurogesX Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-08-2010

NeurogesX Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-13-2010

NeurogesX Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 08-11-2010